Literature DB >> 35146362

Development of post-COVID-19 cardiovascular events: an analysis of clinical features and risk factors from a single hospital retrospective study.

Gianluca Cuomo1, Cinzia Puzzolante1, Vittorio Iadisernia1,2, Antonella Santoro1, Marianna Menozzi1, Federica Carli1, Margherita Digaetano1, Gabriella Orlando1, Erica Franceschini1, Andrea Bedini1, Marianna Meschiari1, Lisa Manzini1, Luca Corradi1, Jovana Milic2, Vanni Borghi2, Lucio Brugioni3, Antonello Pietrangelo2,4, Enrico Clini2,5, Massimo Girardis2,6, Giovanni Guaraldi1,2, Cristina Mussini1,2.   

Abstract

Cardiovascular complications after a SARS-CoV-2 infection are a phenomenon of relevant scientific interest. The aim of this study was to analyze the onset of post-COVID-19 cardiovascular events in patients hospitalized in a tertiary care center. This is a retrospective study conducted on patients hospitalized over a period of three months. The patients were older than 18 years of age and had a diagnosis of COVID-19 infection confirmed from a nasopharyngeal swab sample. Anamnestic and clinical-laboratory data were collected. Cardiovascular events at 30 days were defined as follows: arrhythmias, myocardial infarction, myocarditis, and pulmonary embolism. Univariate analysis (Student's t-test or Mann-Whitney U test, as appropriate) and multivariate analysis (multinomial logistic regression) were applied to the data. A total of 394 patients were included; they were mostly males and had a median age of 65.5 years. Previous cardiovascular disease was present in 14.7% of patients. Oxygen therapy was required for 77.9%, and 53% received anticoagulant therapy. The overall 30-day mortality was 20.3%. A cardiovascular event developed in 15.7% of the subjects. These were mainly pulmonary embolism (9.4%), followed by arrhythmias (3.3%), myocardial infarction (2.3%), and myocarditis (0.8%). Patients who developed cardiovascular events upon univariate analysis were significantly older, with major comorbidities, a more compromised respiratory situation, and a higher mortality rate. Multivariate analysis revealed independent factors that were significantly associated with the development of cardiovascular events: hypertension, endotracheal intubation, and age older than 75 years. In patients with COVID-19, the development of a cardiovascular event occurs quite frequently and is mainly seen in elderly subjects with comorbidities (especially hypertension) in the presence of a severe respiratory picture.
Copyright © 2016 - 2021 InfezMed.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; cardiovascular diseases

Year:  2021        PMID: 35146362      PMCID: PMC8805477          DOI: 10.53854/liim-2904-6

Source DB:  PubMed          Journal:  Infez Med        ISSN: 1124-9390


  46 in total

Review 1.  COVID-19-associated coagulopathy: a concise review on pathogenesis and clinical implications.

Authors:  Sahar Memar Montazerin; Homa Najafi; Fahimehalsadat Shojaei; Gerald Chi; Sogand Goudarzi; Sadaf Sharfaei; Farima Kahe; Shakiba Hassanzadeh
Journal:  Infez Med       Date:  2021-03-01

2.  Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China.

Authors:  Rossella Porcheddu; Caterina Serra; David Kelvin; Nikki Kelvin; Salvatore Rubino
Journal:  J Infect Dev Ctries       Date:  2020-02-29       Impact factor: 0.968

Review 3.  Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS.

Authors:  Jordi Navarro; Adrian Curran
Journal:  HIV AIDS (Auckl)       Date:  2016-10-31

4.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

Review 5.  Cardiac and arrhythmic complications in patients with COVID-19.

Authors:  Adriano Nunes Kochi; Ana Paula Tagliari; Giovanni Battista Forleo; Gaetano Michele Fassini; Claudio Tondo
Journal:  J Cardiovasc Electrophysiol       Date:  2020-04-13

Review 6.  Clinical Presentation of COVID-19: Case Series and Review of the Literature.

Authors:  Margherita Macera; Giulia De Angelis; Caterina Sagnelli; Nicola Coppola
Journal:  Int J Environ Res Public Health       Date:  2020-07-14       Impact factor: 3.390

Review 7.  COVID-19 and cardiovascular diseases.

Authors:  Francesca Mai; Rita Del Pinto; Claudio Ferri
Journal:  J Cardiol       Date:  2020-07-22       Impact factor: 3.159

8.  A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.

Authors:  Bin Cao; Yeming Wang; Danning Wen; Wen Liu; Jingli Wang; Guohui Fan; Lianguo Ruan; Bin Song; Yanping Cai; Ming Wei; Xingwang Li; Jiaan Xia; Nanshan Chen; Jie Xiang; Ting Yu; Tao Bai; Xuelei Xie; Li Zhang; Caihong Li; Ye Yuan; Hua Chen; Huadong Li; Hanping Huang; Shengjing Tu; Fengyun Gong; Ying Liu; Yuan Wei; Chongya Dong; Fei Zhou; Xiaoying Gu; Jiuyang Xu; Zhibo Liu; Yi Zhang; Hui Li; Lianhan Shang; Ke Wang; Kunxia Li; Xia Zhou; Xuan Dong; Zhaohui Qu; Sixia Lu; Xujuan Hu; Shunan Ruan; Shanshan Luo; Jing Wu; Lu Peng; Fang Cheng; Lihong Pan; Jun Zou; Chunmin Jia; Juan Wang; Xia Liu; Shuzhen Wang; Xudong Wu; Qin Ge; Jing He; Haiyan Zhan; Fang Qiu; Li Guo; Chaolin Huang; Thomas Jaki; Frederick G Hayden; Peter W Horby; Dingyu Zhang; Chen Wang
Journal:  N Engl J Med       Date:  2020-03-18       Impact factor: 91.245

9.  Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin.

Authors:  Hongde Hu; Fenglian Ma; Xin Wei; Yuan Fang
Journal:  Eur Heart J       Date:  2021-01-07       Impact factor: 29.983

10.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Authors:  Zunyou Wu; Jennifer M McGoogan
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

View more
  2 in total

1.  Development of a nomogram to assess the impact of the myocardial injury on the prognosis of COVID-19 patients.

Authors:  Mengdi Jin; Zhijun Li; Xinwei Li; Mengtong Xie; Weizhen Li; Lizhe Ai; Yaoyao Sun; Xiaodan Cheng; Yan Sheng; Jinnan Zhang; Nan Jiang; Qiong Yu
Journal:  Infez Med       Date:  2022-06-01

2.  Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis.

Authors:  Ryan Ruiyang Ling; Kollengode Ramanathan; Felicia Liying Tan; Bee Choo Tai; Jyoti Somani; Dale Fisher; Graeme MacLaren
Journal:  Lancet Respir Med       Date:  2022-04-11       Impact factor: 102.642

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.